TY - JOUR
T1 - A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis
AU - Reeves, Rachel M
AU - van Wijhe, Maarten
AU - Lehtonen, Toni
AU - Stona, Luca
AU - Teirlinck, Anne C
AU - Vazquez Fernandez, Liliana
AU - Li, You
AU - Osei-Yeboah, Richard
AU - Fischer, Thea K
AU - Heikkinen, Terho
AU - van Boven, Michiel
AU - Bøås, Håkon
AU - Donà, Daniele
AU - Barbieri, Elisa
AU - Campbell, Harry
AU - RESCEU Investigators
N1 - © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].
PY - 2022/8/12
Y1 - 2022/8/12
N2 - BACKGROUND: Since the widespread adoption of palivizumab prophylaxis in Europe, there have been a number of clinical practice guidelines (CPGs) published for the prevention of respiratory syncytial virus (RSV) infection in children. The aim of this systematic review was to identify CPGs for the prevention of RSV infection across Europe.METHODS: We performed a systematic literature search and contacted European influenza and respiratory virus networks and public health institutions, to identify national CPGs for the prevention of RSV infection. The Reporting Items for practice Guidelines in Healthcare (RIGHT) Statement checklist was applied to extract data and review the quality of reporting.RESULTS: A total of 20 national CPGs were identified, all published between 2000 and 2018. The greatest discrepancy between guidelines was the recommendations for palivizumab prophylaxis for premature infants, with recommendations varying by gestational age. All guidelines recommended or considered the use of palivizumab in infants with bronchopulmonary dysplasia, 85% (n = 17) in children with congenital heart disease (CHD), and 60% (n = 12) in children with severe combined immunodeficiency.CONCLUSIONS: We recommend that agencies publishing RSV prevention guidelines adopt the RIGHT reporting requirements when updating these guidelines to improve the presentation of the evidence-base for decisions.
AB - BACKGROUND: Since the widespread adoption of palivizumab prophylaxis in Europe, there have been a number of clinical practice guidelines (CPGs) published for the prevention of respiratory syncytial virus (RSV) infection in children. The aim of this systematic review was to identify CPGs for the prevention of RSV infection across Europe.METHODS: We performed a systematic literature search and contacted European influenza and respiratory virus networks and public health institutions, to identify national CPGs for the prevention of RSV infection. The Reporting Items for practice Guidelines in Healthcare (RIGHT) Statement checklist was applied to extract data and review the quality of reporting.RESULTS: A total of 20 national CPGs were identified, all published between 2000 and 2018. The greatest discrepancy between guidelines was the recommendations for palivizumab prophylaxis for premature infants, with recommendations varying by gestational age. All guidelines recommended or considered the use of palivizumab in infants with bronchopulmonary dysplasia, 85% (n = 17) in children with congenital heart disease (CHD), and 60% (n = 12) in children with severe combined immunodeficiency.CONCLUSIONS: We recommend that agencies publishing RSV prevention guidelines adopt the RIGHT reporting requirements when updating these guidelines to improve the presentation of the evidence-base for decisions.
KW - palivizumab
KW - prophylaxis
KW - RSV guidelines Europe
KW - Respiratory Syncytial Virus Infections/drug therapy
KW - Humans
KW - Antibodies, Monoclonal, Humanized/therapeutic use
KW - Infant
KW - Hospitalization
KW - Respiratory Syncytial Viruses
KW - Palivizumab/therapeutic use
KW - Antiviral Agents/therapeutic use
KW - Child
KW - Infant, Newborn
UR - http://www.scopus.com/inward/record.url?scp=85136342751&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiac059
DO - 10.1093/infdis/jiac059
M3 - Review
C2 - 35333332
SN - 0022-1899
VL - 226
SP - S110-S116
JO - The Journal of infectious diseases
JF - The Journal of infectious diseases
IS - Suppl 1
ER -